MIV-410

MIV-410 is a small molecule nucleoside analog prodrug developed by Medivir for the treatment of shingles (Herpes Zoster). It is designed to be converted in vivo into its active metabolite, 2',3'-dideoxy-3'-fluoroguanosine (FLG). The active triphosphate form of FLG acts as a potent and selective inhibitor of viral DNA polymerase, specifically targeting the Varicella-zoster virus (VZV). By competing with natural deoxyguanosine triphosphate (dGTP), it incorporates into the nascent viral DNA strand and causes premature chain termination, thereby halting viral replication. Although MIV-410 demonstrated efficacy in Phase 2 clinical trials, its development was terminated by Medivir in the early 2000s.

Other names

FLG prodrug